Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

Draft scope documents

• Draft scope (post-referral) (PDF 139 KB)

  Published:

  29 February 2016

• Provisional matrix (post-referral) (PDF 95 KB)

  Published:

  29 February 2016